cytopenia; pancreatic dysfunction involves both the exocrine and endocrine pancreas manifesting as pancreatic insufficiency and presents as failure to thrive due to low or absent production of pancreatic enzymes and insulin-dependent type 1 diabetes mellitus (Pearson et al., 1979; Stoddard, McCurnin, Shultenover, Wright, & deLemos, 1981) ; kidney dysfunction ranges from mild proximal tubulopathy to chronic kidney disease that requires dialysis and/or kidney transplantation. PS patients may develop phenotypic transformation to have Kearns-Sayre Syndrome (KSS) later (Grady et al., 2014; Kabunga et al., 2015) .
The literature review of previously reported patients with
Pearson syndrome includes cardiac functional decline (Krauch, Wilichowski, Schmidt, & Mayatepek, 2002) but there are no cardiac conduction abnormalities that have been described to date.
Cardiac abnormalities have not yet been regarded as a major feature of Pearson syndrome. In our report, we aim to describe the cardiac conduction defect that was found in our patient, its treatment plan and outcome.
| C A S E PRE S ENTATI ON
A 7year-old girl with Pearson marrow-pancreas syndrome characterized by mitochondrial dysfunction, refractory anemia, neutropenia, thrombocytopenia, exocrine pancreatic insufficiency, insulin-dependent type 1 diabetes mellitus, proximal renal tubular acidosis/ Fanconi's anemia with stage IV chronic kidney disease, short stature, generalized hypotonia and slapping gait, mild-moderately severe sensorineural hearing loss, exotropia, and corneal clouding with photophobia that required corneal transplant was evaluated in the pediatric cardiology clinic for her cardiac status after she was noted to have a sudden increase in heart rate during the recovery phase of anesthesia. Diagnosis of mitochondrial abnormality was made at 2 years of age and her diagnosis of Pearson marrow-pancreas syndrome was confirmed at age 3 years by the finding of large heteroplasmic deletions of mitochondrial DNA (mtDNA) m.6249_14098del7850 in blood cells by next-generation sequencing (NGS) analysis and Southern blot analysis. During her initial evaluation in the pediatric electrophysiology clinic, she was asymptomatic and denied chest pain, palpitations, activity intolerance, presyncope, or syncope. She had no previous history of cardiovascular disease. She was born at full term to healthy nonconsanguineous parents with an unremarkable in-utero and birth history, and an uneventful newborn period. She has two healthy older siblings.
On physical examination, she was a cheerful 7-year-old in no apparent distress, unremarkable cardiac and respiratory findings, and 2 + palpable peripheral pulses. Her blood pressure and pulse rate were 101/62 mmHg and 114/min, respectively. Her pulse oximetry saturation was 99%. Given the progressive nature of her infrahisian block and the progressive nature of her PS, she was planned for prophylactic pacemaker placement, given other similar mitochondrial diseases benefit from pacemaker implantation (Epstein et al., 2008) . Benefits versus risks of transvenous pacemaker versus epicardial pacemaker were considered. Transvenous single-chamber ventricular pacemaker was believed to be the best option due to her pancytopenic status, and a possibility of kidney and/or bone marrow transplantation in the near future that would necessitate immunosuppressive medications which increases her risk of infection, given the lower risk for endocarditis. She underwent successful single-chamber ventricular pacemaker implantation. The pacemaker was set to VVI at 60 bpm.
The initial values at implant were stable with optimum thresholds, impedances, and sensing. The patient was followed up in the pediatric electrophysiology clinic 12 days as well as 3 months after the pacemaker placement. She was doing well with improved threshold, impedance, and sensing values. At 3-month follow-up, no episodes of nonsustained ventricular arrhythmias were noted by her device. with worsening cardiac function that mainly involved the left ventricle (Krauch et al., 2002) . An autopsy study of a 3-year-old girl found that there was markedly reduced mitochondrial enzyme activity in the heart and other organs like the liver and muscles, although there were no clinical cardiac manifestations in that patient (Sato et al., 2015) . Cardiovascular pathologies most commonly determine life expectancy, but little is known about the nature of the underlying cardiac abnormality in patients with PS. Kearns-Sayre syndrome (KSS) later, which is an example of tissue-specific modifications of mitochondrial heteroplasmy (mitotic segregation) (Grady et al., 2014; Kabunga et al., 2015) . KSS is another mitochondrial disorder with onset before 20 years of age that classically involves the eyes and heart. Cardiac involvement in KSS manifests as conduction abnormalities of varying degrees in more than 50% and sudden cardiac death is reported in as high as 20%
| D ISCUSS I ON
of the patients (Chawla, Coku, Forbes, & Kannan, 2008; Kabunga et al., 2015) . Many of the mitochondrial DNA deletion syndromes (PS, KSS, chronic progressive external ophthalmoplegia (CPEO), and others) have reduced enzymatic activities of common mitochondrial respiratory chain complexes (MRCC) (Sato et al., 2015) . We hypothesize that the same mechanism that involves the cardiac muscles and conduction system in KSS could possibly be the reason for the cardiac involvement in PS as well, but this needs to be further studied and confirmed through molecular diagnostics.
It is possible that cardiac involvement may be a later feature of PS; more than half of the patients die before the age of 4 years and our patient is a 7-year-old. Deleted mitochondrial DNA (mtDNA) may be distributed unevenly in various tissues of the body. This is probably another critical determinant of the varied phenotypic presentation, determining the varying degrees of involvement of the organ systems. (Gregoratos et al., 1998) . To our knowledge, this is the only patient-reported thus far to have this cardiac conduction defect associated with the classical features of PS, and also to undergo prophylactic pacemaker implantation.
| CON CLUS ION
Our report demonstrates that patients with Pearson marrow-pancreas syndrome may also have cardiac involvement that manifests as conduction abnormalities. Thus, one should evaluate and consider that patients diagnosed with Pearson syndrome have electrocardiographic and echocardiographic studies at disease diagnosis, and also need follow-up periodically thereafter. If they are found to have alternating bundle branch blocks, we recommend consideration of prophylactic pacemaker placement, given the progressive nature of the disease. If they also have documented ventricular tachycardia (VT), it would be reasonable to assess the cause of VT (evaluation for the presence of ventricular scarring or inducible VT) before a decision on the kind of permanent device (pacemaker or intracardiac device (ICD) implantation) is made, and as was the case in this patient, continued serial monitoring and potential treatment of nonsustained ventricular tachycardia must be considered. This case highlights the importance of having cardiologists and electrophysiologists as part of the multidisciplinary team to ensure careful and timely intervention, and also to prevent sudden cardiac death from an undiagnosed heart block.
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